Company intelligence
Aspen Neuroscience, Inc.
Developing autologous iPSC-derived cell replacement therapies for Parkinson’s disease and other CNS disorders
About Aspen Neuroscience, Inc.
Aspen Neuroscience is a clinical-stage regenerative medicine biotechnology company developing autologous induced pluripotent stem cell (iPSC)-derived therapies, beginning with Parkinson’s disease (PD). Our lead investigational therapy, sasineprocel (ANPD001), is designed to replace lost dopaminergic neurons and reconstruct the underlying neural circuitry to restore function and potentially slow disease progression—without the need for immunosuppression. At Aspen, our team is passionate about bringing our world class science and manufacturing to patients. We aim to transform the lives of people living with PD with our personalized regenerative therapies that offer real hope where none existed before.
Verified activity
Signals from Aspen Neuroscience, Inc.
3 published signals
Presence & Recognition
Aspen Neuroscience, Inc. welcomed longtime Parkinson’s caregiver Paul Kidwell for a personal conversation about caring for his late wife, Aibai, throughout her 18-year Parkinson’s journey.
Reported by Aspen Neuroscience, Inc.
Presence & Recognition
Aspen Neuroscience, Inc. shared its progress in advancing autologous iPSC-derived neuron replacement for Parkinson's disease at the From the Laboratory to the Clinic 2026 conference held at Trinity College, Oxford.
Reported by Xiaokui Zhang, PhD
Presence & Recognition
Aspen Neuroscience, Inc. researcher Xiaokui Zhang PhD presented From Patient Cells to Brain Repair: Autologous iPSC-Derived Neuron Replacement for Parkinson’s Disease at the From the Laboratory to the Clinic: Complex Pathogenesis of Disease conference at Trinity College, Oxford.
Reported by Aspen Neuroscience, Inc.